Biotech
Commented by Fabian Lorenz on August 29th, 2024 | 07:00 CEST
Up to 200% upside potential! Evotec, Tui, and Almonty Industries shares!
Will Evotec's share price double or fall by 40%? Analyst opinions on the ailing biotech company differ widely. The management offers some encouragement, as insiders have been buying shares of Evotec. Almonty is currently performing strongly. The shares of the tungsten producer are at a yearly high. The half-year figures have been convincing, and analysts see around 200% upside potential. Has the share finally initiated its revaluation? By contrast, experts remain skeptical about Tui. Business is booming, but for how much longer?
Read
Commented by Stefan Feulner on August 28th, 2024 | 07:15 CEST
Siemens Healthineers, Vidac Pharma, Viking Therapeutics - Powerful movements
After the hype during the COVID-19 pandemic, biotech stocks have lagged behind the broader market, allowing major technology companies to take the lead. Smaller, capital-intensive companies, in particular, have suffered from the high interest rate level. However, this is likely to change soon. On the one hand, monetary policy is expected to be eased, and on the other hand, demographic changes point to a long-term explosion in demand for new medications.
Read
Commented by André Will-Laudien on August 28th, 2024 | 07:00 CEST
Starting signal for a rally? BioNTech, Pfizer, and Bayer under scrutiny, Major news expected from Cardiol Therapeutics and Evotec
Despite all the prophecies of doom, life goes on in the biotech sector. With a medium-term focus, it makes sense to bet on management qualities, as the recent price drops were partially too severe, but the research approaches promise a better future. BioNTech and Pfizer still have to deal with the COVID-19 issue, while Bayer has now taken all measures to achieve a turnaround. The situation at Cardiol Therapeutics and Evotec is particularly interesting, as the members of the Management Board continue to buy shares regularly.
Read
Commented by Juliane Zielonka on August 23rd, 2024 | 07:15 CEST
Vidac Pharma, Bavarian Nordic, Palantir - Dream team in travel health and AI: 3 companies in focus
According to Marketresearch.biz, the travel health market is experiencing considerable growth. It is expected to grow from USD 78.5 billion in 2022 to USD 475.8 billion by 2032. This corresponds to an impressive annual growth rate of 20.3% between 2023 and 2032. Travel health can mean avoiding skin cancer while on vacation, but if it does occur, Vidac Pharma is at the forefront with a personalized medicine approach that excites investors. Listening to the WHO, it is clear that monkeypox is once again spreading and posing health risks. As a German-Danish biotech company, Bavarian Nordic has the vaccine answer and is revising its forecasts upwards thanks to strong market demand. Anyone travelling should also keep an eye on geopolitical tensions. Palantir has recently made a name for itself by supporting governments with AI products. Now, Palantir is bringing on board a man with an immense track record in US politics. Today, we focus on three promising investment opportunities.
Read
Commented by Armin Schulz on August 21st, 2024 | 07:00 CEST
Bayer, Cardiol Therapeutics, Evotec - Is monkeypox providing new momentum in the biotech and pharma sector?
The recent outbreak of monkeypox has once again highlighted the critical importance of a rapid and effective response to emerging health threats. This situation highlights the significant role of the biotech and pharmaceutical industries in addressing such challenges. Some companies are focused on combating infectious diseases such as monkeypox, while others are developing innovative therapies for chronic, severe, or rare diseases. Today, we look at three companies committed to improving people's health.
Read
Commented by Juliane Zielonka on August 9th, 2024 | 06:30 CEST
Cardiol Therapeutics, Novo Nordisk, Bayer - Pharma stocks in focus
The healthcare sector promises further blockbusters for investors. Cardiol Therapeutics impresses with its promising Phase II study of CardiolRx™ for the treatment of the heart disease pericarditis. The growing market for pericarditis treatments offers the Company great potential, which has also been positively noted by analysts. The Danish company Novo Nordisk is experiencing impressive growth thanks to its GLP-1-based diabetes and obesity drugs. The active ingredient is causing a stir in the celebrity scene as an off-label weight loss injection, further boosting the Company's sales figures. Bayer AG is facing up to its challenges. Despite slight revenue growth in the second quarter of 2024, profits declined. Nevertheless, CEO Bill Anderson believes the Company is on the right track, particularly thanks to progress in the pharmaceutical pipeline. We have three companies in focus.
Read
Commented by Fabian Lorenz on August 8th, 2024 | 07:00 CEST
Siemens Energy tops, Evotec shocks, and what is causing the dynaCERT share to explode?
The Evotec share lost more than 35% yesterday. The share was already trading at a multi-year low before this drop. Investors were particularly shocked by the adjustment to the EBITDA forecast. Additionally, the biotech company indicated that it plans to downsize. This year, Siemens Energy has shown how quickly a difficult situation can be resolved. On the verge of bankruptcy at the end of 2023, it is back on track, although not thanks to renewable energies. In contrast, dynaCERT has yet to see its share price explode. A former Daimler manager will take the helm in the coming days and is expected to secure orders in Europe. Additionally, dynaCERT investors are waiting for VERRA certification.
Read
Commented by André Will-Laudien on August 5th, 2024 | 07:00 CEST
In the fight against cancer - 100% performance possible: Bayer, Vidac Pharma, Evotec, BioNTech and CureVac
The FED is giving new hope to the Biotech sector with lower interest rates, which are expected to happen as early as September. This is important for the near future, as share prices are lagging dramatically behind the NASDAQ performance in 2024. However, if extensive research can be financed under more favourable conditions, this should also help the stock market prices recover. The business models contain some good news, and selection is now crucial. We assist in selecting attractive stocks and provide entry levels.
Read
Commented by Fabian Lorenz on August 1st, 2024 | 06:30 CEST
Evotec slashed, Bayer sued, and Cardiol Therapeutics share praised
Anyone speculating on a quick rebound for Evotec will be disappointed. At present, one can at most speak of a bottoming out. It is fitting that a renowned analyst has slashed his price target for the German biotech share. Or is it only half as bad? Analysts see massive upside potential for the shares of Cardiol Therapeutics. The share price has more than doubled in the current year and is currently consolidating. There is an exciting entry opportunity now that positive study results have fizzled out on the stock market. Bayer, on the other hand, simply cannot get out of the world's courtrooms. In the US, a new lawsuit has been filed against the Leverkusen-based company; in another case, a multi-million dollar payment must be made.
Read
Commented by Stefan Feulner on July 30th, 2024 | 06:30 CEST
Viking Therapeutics, Vidac Pharma, Merck KGaA - In the footsteps of Novo Nordisk
Drugs for the treatment of diabetes and obesity have helped the pharmaceuticals manufacturer Novo Nordisk to become the most valuable listed company in Europe. But the competition is not sleeping. Many promising biotechs are already presenting new preparations that could overtake the Danes in the long term. Young companies with the chance of the next blockbuster also have great potential in other areas, such as cancer research.
Read